▎Armstrong2025年12月24日,丽珠医药IL-17A/F抗体莱康奇塔单抗注射液的上市申请获得NMPA受理,为首款申报上市的国产IL-17A/F抗体。今年7月,丽珠医药宣布莱康奇塔单抗在银屑病三期临床中头对头击败可善挺。研究数据表明,莱康奇塔单抗起效更快、短期疗效优异、长期强效持久、用药便捷性高(12周后每8周一次维持治疗)、安全性优异。总结Th17通路在银屑病、银屑病关节炎、强制性...
Source Link▎Armstrong2025年12月24日,丽珠医药IL-17A/F抗体莱康奇塔单抗注射液的上市申请获得NMPA受理,为首款申报上市的国产IL-17A/F抗体。今年7月,丽珠医药宣布莱康奇塔单抗在银屑病三期临床中头对头击败可善挺。研究数据表明,莱康奇塔单抗起效更快、短期疗效优异、长期强效持久、用药便捷性高(12周后每8周一次维持治疗)、安全性优异。总结Th17通路在银屑病、银屑病关节炎、强制性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.